Liberum Capital upgraded shares of Astrazeneca PLC (NYSE:AZN) from a hold rating to a buy rating in a research report sent to investors on Friday.

A number of other research analysts have also weighed in on AZN. Cantor Fitzgerald reissued a buy rating on shares of Astrazeneca PLC in a research note on Thursday, July 28th. JPMorgan Chase & Co. reissued a neutral rating on shares of Astrazeneca PLC in a research note on Sunday, July 31st. Citigroup Inc. reissued a buy rating on shares of Astrazeneca PLC in a research note on Wednesday, August 10th. Shore Capital reissued a hold rating on shares of Astrazeneca PLC in a research note on Wednesday, August 10th. Finally, Beaufort Securities reissued a hold rating on shares of Astrazeneca PLC in a research note on Thursday, August 11th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Astrazeneca PLC has a consensus rating of Buy and a consensus target price of $37.61.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Astrazeneca PLC (NYSE:AZN) opened at 26.71 on Friday. The firm has a market capitalization of $67.58 billion, a PE ratio of 27.41 and a beta of 0.83. Astrazeneca PLC has a 1-year low of $25.88 and a 1-year high of $35.04. The company’s 50-day moving average price is $28.71 and its 200 day moving average price is $30.78.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the company posted $1.03 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Astrazeneca PLC will post $3.02 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Astrazeneca PLC (AZN) Raised to “Buy” at Liberum Capital” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of international trademark and copyright law. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2016/11/30/astrazeneca-plc-azn-raised-to-buy-at-liberum-capital.html.

Institutional investors have recently bought and sold shares of the company. AMP Capital Investors Ltd increased its position in shares of Astrazeneca PLC by 205.9% in the first quarter. AMP Capital Investors Ltd now owns 73,409 shares of the company’s stock worth $2,079,000 after buying an additional 49,409 shares during the last quarter. Royal Bank of Canada increased its position in shares of Astrazeneca PLC by 24.2% in the first quarter. Royal Bank of Canada now owns 722,283 shares of the company’s stock worth $20,339,000 after buying an additional 140,921 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock worth $964,000 after buying an additional 1,027 shares during the last quarter. Logan Capital Management Inc. increased its position in shares of Astrazeneca PLC by 0.6% in the first quarter. Logan Capital Management Inc. now owns 19,698 shares of the company’s stock worth $554,000 after buying an additional 109 shares during the last quarter. Finally, First Republic Investment Management Inc. increased its position in shares of Astrazeneca PLC by 14.9% in the first quarter. First Republic Investment Management Inc. now owns 134,932 shares of the company’s stock worth $3,800,000 after buying an additional 17,480 shares during the last quarter. Institutional investors and hedge funds own 13.05% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.